Related references
Note: Only part of the references are listed.Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging study
Christie M. Ballantyne et al.
AMERICAN HEART JOURNAL (2012)
Torcetrapib impairs endothelial function in hypertension
Branko Simic et al.
EUROPEAN HEART JOURNAL (2012)
Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy
Kausik Ray et al.
HEART (2012)
Updated evidence on early statin therapy for acute coronary syndromes: Meta-analysis of 18 randomized trials involving over 14,000 patients
Matthias Briel et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2012)
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Heart Disease and Stroke Statistics-2011 Update A Report From the American Heart Association
Veronique L. Roger et al.
CIRCULATION (2011)
Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol A Randomized Controlled Trial
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure
Guoqing Cao et al.
JOURNAL OF LIPID RESEARCH (2011)
Meta-analysis: Statin Therapy Does Not Alter the Association Between Low Levels of High-Density Lipoprotein Cholesterol and Increased Cardiovascular Risk
Haseeb Jafri et al.
ANNALS OF INTERNAL MEDICINE (2010)
Cholesteryl Ester Transfer Protein and Mortality in Patients Undergoing Coronary Angiography The Ludwigshafen Risk and Cardiovascular Health Study
Andreas Ritsch et al.
CIRCULATION (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
Daniel Bloomfield et al.
AMERICAN HEART JOURNAL (2009)
The Pharmacology and Off-Target Effects of Some Cholesterol Ester Transfer Protein Inhibitors
Menno Vergeer et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition
Xiao Hu et al.
ENDOCRINOLOGY (2009)
Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia
Frank Hermann et al.
THROMBOSIS RESEARCH (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis
Matthias Briel et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia
Maryse Guerin et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity A Pooled Analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) Trials
Menno Vergeer et al.
CIRCULATION (2008)
Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk
Alexander Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies
Rajesh Krishna et al.
LANCET (2007)
Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion - A meta-analysis
Tong Liu et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Effect of torcetrapib on the progression of coronary atherosclerosis
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population
Jelena Vekic et al.
CLINICAL BIOCHEMISTRY (2007)
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels
Michael H. Davidson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin
James M. McKenney et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data
Alan D. Lopez et al.
LANCET (2006)
Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial
JD Otvos et al.
CIRCULATION (2006)
Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: Role of CETP and triglycerides
R de Vries et al.
DIABETES (2005)
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with Pravastatin in type II dyslipidemia
JA Kuivenhoven et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds - A meta-analysis of randomized controlled trials
RS Birjmohun et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia
RJ Bisoendial et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
ABCA1-dependent lipid eff lux to apolipoprotein A-1 mediates HDL particle formation and decreases VLDL secretion from murine hepatocytes
D Sahoo et al.
JOURNAL OF LIPID RESEARCH (2004)
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans - A randomized phase II dose-response study
GJ de Grooth et al.
CIRCULATION (2002)
A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
H Okamoto et al.
NATURE (2000)
Share Paper
